Intrinsiqq
YD Bio Limited logo

YD Bio Limited

YDES

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$322M
EPS-$0.12
P/E-40.25
P/FCF-40.10
EV/EBITDA-60.03
FCF Yield–
Div. Yield–
Net Debt/FCF0.7x
YD Bio Limited intrinsic value
52-Week Range
$1.90$13.91

Profitability & Returns

Revenue (TTM)

$597K

▲ +16.9% YoY

Net Income (TTM)

-$8M

▼ -488.8% YoY

Op. Margin

-882.74%

▼ -596.2pp YoY

ROIC

-125.75%

▼ -91.2pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$8M

▼ -94.4% YoY

Op. Cash Flow (TTM)

-$7M

▼ -439.5% YoY

Net Debt

-$6M

Net Cash Position

Cash & Equiv.

$6M

Continue Research

Peers

Biotechnology · Pick stocks to compare with YDES

CompareIntrinsic value
PROGEN.XSTOProstatype Genomics AB
€0.01+3.45%10
OXUR.XBRUOxurion NV
€0.00+0.00%15
ITOCPheton Holdings Ltd.
$1.59+6.00%18
ATORX.XSTOAlligator Bioscience AB
kr 0.01-5.68%10
TNG.XPARTransgene SA
€0.69+0.43%10
NANECH.XSTONanoEcho AB
No recent price10
BIBB.XSTOBibbinstruments AB
€0.03+7.69%10
TANAFTian'an Technology Group Ltd.
$0.10+0.00%61

Held by ETFs

YDES is in 1 US ETF. The largest of them, with YDES's weight in each:

YD Bio (YDES) in four numbers

Fair value (revenue)
$0.02
Price $4.83 is 29524% above it.
Intrinsic Value
Quality score
25/100
Best check: revenue growth, 30.6%. Weakest: return on capital, -125.8%.
Quality
Dividend
None
No dividend in the company filings we hold.
Dividends
P/E
-40.25
Negative: a loss over the last twelve months. Price to free cash flow -40.10.
Financials

Questions about YD Bio

Is YD Bio (YDES) overvalued?

At $4.83, YD Bio's price is 29524% above the $0.02 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is YD Bio's fair value?

Intrinsiqq's calculator puts YD Bio's fair value at $0.02 a share. It grows revenue per share 5% a year for 5 years, applies an exit P/S of 2.3, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.01. Every input can be changed on the Intrinsic Value tab.

Is YD Bio a high-quality business?

YD Bio scores 25 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from company filings. Its best check is revenue growth at 30.6%, and its weakest is return on capital at -125.8%. The Quality tab shows every check against its target.

Does YD Bio (YDES) pay a dividend?

No. YD Bio (YDES) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing YDES

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.